董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy A. Springer | 男 | Independent Director | 77 | 24.80万美元 | 538.24 | 2026-04-01 |
| Phillip Donenberg | 男 | Independent Director | 65 | 25.38万美元 | 0.95 | 2026-04-01 |
| Stefan Vitorovic | 男 | Independent Director | 41 | 25.19万美元 | 未持股 | 2026-04-01 |
| Praveen Tipirneni | 男 | Independent Director | 57 | 25.00万美元 | 1.52 | 2026-04-01 |
| Alise Reicin | 女 | Director,President and Chief Executive Officer | 65 | 735.16万美元 | 33.48 | 2026-04-01 |
| Franois Nader | -- | Chair of the Board | -- | 未披露 | 未持股 | 2026-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Lochner | 男 | Chief Financial Officer | 44 | 310.11万美元 | 0.60 | 2026-04-01 |
| Alise Reicin | 女 | Director,President and Chief Executive Officer | 65 | 735.16万美元 | 33.48 | 2026-04-01 |
| Peter McNamara | 男 | Chief Scientific Officer | 54 | 未披露 | 未持股 | 2026-04-01 |
| Marcella K. Ruddy | 女 | Chief Medical Officer | 62 | 306.96万美元 | 11.09 | 2026-04-01 |
| Marc Schwabish | 男 | Chief Business Officer | 45 | 未披露 | 未持股 | 2026-04-01 |
董事简历
中英对照 | 中文 | 英文- Timothy A. Springer
-
TimothyA.Springer自2016年6月起担任我们的董事会成员，自2008年12月起担任我们的科学顾问。自1989年以来，Springer博士担任哈佛医学院（Harvard Medical School）的Latham Family教授。他也曾担任Boston Children&8217；s Hospital的细胞和分子医学项目的高级研究员（2012年以来），以及Harvard Medical School的生物化学和分子药理学教授，以及Boston Children&8217；s Hospital的医学教授（2011年以来）。Springer博士是Leukosite的创始人，这是一家1999年被Millennium Pharmaceuticals收购的生物技术公司。此外，他是Scholar Rock and Morphic Therapeutic的创始人、投资者和董事会成员。Springer博士是美国国家科学院（National Academy of Sciences）的成员，他的荣誉包括Crafoord Prize、美国免疫学家协会功勋职业奖、美国血液学会Stratton奖章和美国心脏协会基础研究奖。Springer博士在加州大学伯克利分校（University of California，Berkeley）获得学士学位，在哈佛大学（Harvard University）获得博士学位。
Timothy A. Springer,has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he was a founder, investor and board member of Morphic Therapeutic until its acquisition by Eli Lilly & Co. in 2024, and a founder, investor and former director of Scholar Rock, where he served as a director until May 2019. Dr. Springer is currently a founder and director of Tectonic Therapeutic since 2020 and Seismic Therapeutic since 2020. He is a founder and board member of the Institute for Protein Innovation since 2016 and trustee of the Marine Biological Laboratory since 2019 (both non-profit organizations). Dr. Springer is an elected member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer also received the Albert Lasker Basic Medical Research Award in 2022, and the Robert Koch Prize in 2023. Dr. Springer received a B.A. from the University of California, Berkeley, and a Ph.D. from Harvard University. - TimothyA.Springer自2016年6月起担任我们的董事会成员，自2008年12月起担任我们的科学顾问。自1989年以来，Springer博士担任哈佛医学院（Harvard Medical School）的Latham Family教授。他也曾担任Boston Children&8217；s Hospital的细胞和分子医学项目的高级研究员（2012年以来），以及Harvard Medical School的生物化学和分子药理学教授，以及Boston Children&8217；s Hospital的医学教授（2011年以来）。Springer博士是Leukosite的创始人，这是一家1999年被Millennium Pharmaceuticals收购的生物技术公司。此外，他是Scholar Rock and Morphic Therapeutic的创始人、投资者和董事会成员。Springer博士是美国国家科学院（National Academy of Sciences）的成员，他的荣誉包括Crafoord Prize、美国免疫学家协会功勋职业奖、美国血液学会Stratton奖章和美国心脏协会基础研究奖。Springer博士在加州大学伯克利分校（University of California，Berkeley）获得学士学位，在哈佛大学（Harvard University）获得博士学位。
- Timothy A. Springer,has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he was a founder, investor and board member of Morphic Therapeutic until its acquisition by Eli Lilly & Co. in 2024, and a founder, investor and former director of Scholar Rock, where he served as a director until May 2019. Dr. Springer is currently a founder and director of Tectonic Therapeutic since 2020 and Seismic Therapeutic since 2020. He is a founder and board member of the Institute for Protein Innovation since 2016 and trustee of the Marine Biological Laboratory since 2019 (both non-profit organizations). Dr. Springer is an elected member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer also received the Albert Lasker Basic Medical Research Award in 2022, and the Robert Koch Prize in 2023. Dr. Springer received a B.A. from the University of California, Berkeley, and a Ph.D. from Harvard University.
- Phillip Donenberg
-
Phillip Donenberg是我们的董事会成员，在本招股说明书所包含的注册声明生效后立即生效。自2018年7月16日起，多嫩伯格先生已被任命为Depomed，Inc.的首席财务官兼高级副总裁。在此之前，多嫩伯格先生将继续担任Avexis，Inc.的高级副总裁兼首席财务官，此前他曾于2016年9月至2017年10月担任该公司的Vice President兼公司财务总监。他曾担任RestorGenex Corporation的首席财务官（2014年5月至2016年1月）、Diffusion Pharmaceuticals LLC的首席财务官（2013年9月至2014年5月），以及7Wire Ventures LLC的首席财务官（2016年9月至2014年5月）。在此之前，从1998年7月到2013年6月Biosante Pharmaceuticals，Inc.与ANIP Pharmaceuticals，Inc.合并，Donenberg先生担任Biosante Pharmaceuticals，Inc.的首席财务官。Donenberg先生还拥有在私人控股公司董事会任职的经验。Donenberg先生拥有伊利诺伊大学香槟-厄巴纳商学院（University of Illinois Champaign-Urbana College of Business）的会计学学士学位，并且是一名注册会计师。
Phillip Donenberg,had served on the board of directors and as Audit Committee Chairman of AVROBIO, Inc., a publicly traded gene therapy company, since June 2018, prior to AVROBIO's reverse merger with Tectonic in June 2024. Mr. Donenberg has served on the board of directors and as chairman of the audit committee of Taysha Gene Therapies, Inc., a publicly traded gene therapy company, since August 2020. Mr. Donenberg served as Senior Vice-President and Chief Financial Officer of Jaguar Gene Therapy, LLC, a privately held early-stage gene therapy company, from February 2020 to March 2023. Previously, Mr. Donenberg served as Chief Financial Officer and Senior Vice-President of Assertio Therapeutics, Inc., a pharmaceutical company, from July 2018 to November 2018. He served as Senior Vice-President and Chief Financial Officer of AveXis, Inc., a publicly traded gene therapy company, from 2017 to June 2018 and as Vice-President, Corporate Controller from 2016 to 2017. Mr. Donenberg earned a B.S. in accountancy from the University of Illinois, Champaign-Urbana College of Business and is a Certified Public Accountant. - Phillip Donenberg是我们的董事会成员，在本招股说明书所包含的注册声明生效后立即生效。自2018年7月16日起，多嫩伯格先生已被任命为Depomed，Inc.的首席财务官兼高级副总裁。在此之前，多嫩伯格先生将继续担任Avexis，Inc.的高级副总裁兼首席财务官，此前他曾于2016年9月至2017年10月担任该公司的Vice President兼公司财务总监。他曾担任RestorGenex Corporation的首席财务官（2014年5月至2016年1月）、Diffusion Pharmaceuticals LLC的首席财务官（2013年9月至2014年5月），以及7Wire Ventures LLC的首席财务官（2016年9月至2014年5月）。在此之前，从1998年7月到2013年6月Biosante Pharmaceuticals，Inc.与ANIP Pharmaceuticals，Inc.合并，Donenberg先生担任Biosante Pharmaceuticals，Inc.的首席财务官。Donenberg先生还拥有在私人控股公司董事会任职的经验。Donenberg先生拥有伊利诺伊大学香槟-厄巴纳商学院（University of Illinois Champaign-Urbana College of Business）的会计学学士学位，并且是一名注册会计师。
- Phillip Donenberg,had served on the board of directors and as Audit Committee Chairman of AVROBIO, Inc., a publicly traded gene therapy company, since June 2018, prior to AVROBIO's reverse merger with Tectonic in June 2024. Mr. Donenberg has served on the board of directors and as chairman of the audit committee of Taysha Gene Therapies, Inc., a publicly traded gene therapy company, since August 2020. Mr. Donenberg served as Senior Vice-President and Chief Financial Officer of Jaguar Gene Therapy, LLC, a privately held early-stage gene therapy company, from February 2020 to March 2023. Previously, Mr. Donenberg served as Chief Financial Officer and Senior Vice-President of Assertio Therapeutics, Inc., a pharmaceutical company, from July 2018 to November 2018. He served as Senior Vice-President and Chief Financial Officer of AveXis, Inc., a publicly traded gene therapy company, from 2017 to June 2018 and as Vice-President, Corporate Controller from 2016 to 2017. Mr. Donenberg earned a B.S. in accountancy from the University of Illinois, Champaign-Urbana College of Business and is a Certified Public Accountant.
- Stefan Vitorovic
-
Stefan Vitorovic自2018年3月起担任我们的董事会成员。Vitorovic先生自2017年1月起担任Vida Ventures，LLC或Vida Ventures的联合创始人兼董事总经理。在加入Vida Ventures之前，Vitorovic先生曾担任Third Rock Ventures的负责人，于2014年7月至2017年1月在该公司任职。加入Third Rock Ventures之前，Vitorovic从2012年8月到2014年6月担任TPG Capital梦百合私募股权投资者。Vitorovic先生在斯坦福大学（Stanford University）以优异成绩获得分子与细胞生物学学士学位和分子与细胞生物学硕士学位，并在哈佛大学（Harvard University）获得工商管理硕士学位。
Stefan Vitorovic has served as a member of our board of directors since August 2021. Mr. Vitorovic is the co-founder and Managing Director of Vida Ventures, a role he has served in since January 2017. Prior to founding Vida Ventures, Mr. Vitorovic was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm, from July 2014 to January 2017. At Third Rock, he was part of the founding team of Decibel Therapeutics, Inc., a hearing-focused drug discovery and development platform company. Before Third Rock, he was an investor at TPG Capital from August 2012 to June 2014 where he focused on majority, control stakes in healthcare companies. Mr. Vitorovic worked on a variety of equity and debt financings, including Aptalis Pharmaceutical Technologies now Adare Pharma Solutions and Biomet, Inc. (now Zimmer Biomet Holdings, Inc. (NYSE: ZBH)). Prior to TPG, Mr. Vitorovic was an investment banker at Credit Suisse's healthcare banking group from 2004 to 2008. Mr. Vitorovic currently serves on the board of directors of Praxis Precision Medicines, Inc. (NASDAQ: PRAX), Tectonic Therapeutics, Volastra Therapeutics, Inc., and BAIT Therapeutics, Inc. He was previously a board observer of Oyster Point Pharma, Inc. (NASDAQ: OYST), Dyne Therapeutics (NASDAQ: DYN), and Volastra Therapeutics, Inc., and a board member of Kyverna Therapeutics, Inc. and Sutro Biopharma, Inc. (NASDAQ: STRO). He received a BS with Honors in Biological Sciences and an MS in Biology from Stanford University, where he conducted biomedical research in the lab of Dr. Helen Blau at Stanford Medical School. Mr. Vitorovic received his MBA from Harvard Business School. - Stefan Vitorovic自2018年3月起担任我们的董事会成员。Vitorovic先生自2017年1月起担任Vida Ventures，LLC或Vida Ventures的联合创始人兼董事总经理。在加入Vida Ventures之前，Vitorovic先生曾担任Third Rock Ventures的负责人，于2014年7月至2017年1月在该公司任职。加入Third Rock Ventures之前，Vitorovic从2012年8月到2014年6月担任TPG Capital梦百合私募股权投资者。Vitorovic先生在斯坦福大学（Stanford University）以优异成绩获得分子与细胞生物学学士学位和分子与细胞生物学硕士学位，并在哈佛大学（Harvard University）获得工商管理硕士学位。
- Stefan Vitorovic has served as a member of our board of directors since August 2021. Mr. Vitorovic is the co-founder and Managing Director of Vida Ventures, a role he has served in since January 2017. Prior to founding Vida Ventures, Mr. Vitorovic was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm, from July 2014 to January 2017. At Third Rock, he was part of the founding team of Decibel Therapeutics, Inc., a hearing-focused drug discovery and development platform company. Before Third Rock, he was an investor at TPG Capital from August 2012 to June 2014 where he focused on majority, control stakes in healthcare companies. Mr. Vitorovic worked on a variety of equity and debt financings, including Aptalis Pharmaceutical Technologies now Adare Pharma Solutions and Biomet, Inc. (now Zimmer Biomet Holdings, Inc. (NYSE: ZBH)). Prior to TPG, Mr. Vitorovic was an investment banker at Credit Suisse's healthcare banking group from 2004 to 2008. Mr. Vitorovic currently serves on the board of directors of Praxis Precision Medicines, Inc. (NASDAQ: PRAX), Tectonic Therapeutics, Volastra Therapeutics, Inc., and BAIT Therapeutics, Inc. He was previously a board observer of Oyster Point Pharma, Inc. (NASDAQ: OYST), Dyne Therapeutics (NASDAQ: DYN), and Volastra Therapeutics, Inc., and a board member of Kyverna Therapeutics, Inc. and Sutro Biopharma, Inc. (NASDAQ: STRO). He received a BS with Honors in Biological Sciences and an MS in Biology from Stanford University, where he conducted biomedical research in the lab of Dr. Helen Blau at Stanford Medical School. Mr. Vitorovic received his MBA from Harvard Business School.
- Praveen Tipirneni
-
Praveen Tipirneni，自2024年11月起担任BBOT董事会成员。自2024年6月起，他一直担任Tectonic Therapeutic Inc.（纳斯达克：TECX）（原名AVROBIO，Inc.）的董事会成员。Tipirneni博士此前自2020年2月起在Legacy Tectonic Therapeutic董事会任职。他目前是Morphic Holding, Inc.（纳斯达克：MORF）的首席执行官和董事会成员，自2015年7月起担任该职位。Tipirneni博士获得了麻省理工学院机械工程学士学位、麦吉尔大学医学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
Praveen Tipirneni,has been a member of the board of directors of Tectonic Therapeutic Inc. (Nasdaq: TECX) (formerly known as AVROBIO, Inc.). Dr. Tipirneni previously served on the legacy Tectonic Therapeutic board of directors since February 2020. He is currently the Chief Executive Officer and a member of the board of directors of Morphic Holding, Inc. (Nasdaq: MORF), a position he has held since July 2015. Dr. Tipirneni received a B.A. in Mechanical Engineering from the Massachusetts Institute of Technology, an M.D. from McGill University, and an M.B.A. from the Wharton School of Business at the University of Pennsylvania. - Praveen Tipirneni，自2024年11月起担任BBOT董事会成员。自2024年6月起，他一直担任Tectonic Therapeutic Inc.（纳斯达克：TECX）（原名AVROBIO，Inc.）的董事会成员。Tipirneni博士此前自2020年2月起在Legacy Tectonic Therapeutic董事会任职。他目前是Morphic Holding, Inc.（纳斯达克：MORF）的首席执行官和董事会成员，自2015年7月起担任该职位。Tipirneni博士获得了麻省理工学院机械工程学士学位、麦吉尔大学医学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
- Praveen Tipirneni,has been a member of the board of directors of Tectonic Therapeutic Inc. (Nasdaq: TECX) (formerly known as AVROBIO, Inc.). Dr. Tipirneni previously served on the legacy Tectonic Therapeutic board of directors since February 2020. He is currently the Chief Executive Officer and a member of the board of directors of Morphic Holding, Inc. (Nasdaq: MORF), a position he has held since July 2015. Dr. Tipirneni received a B.A. in Mechanical Engineering from the Massachusetts Institute of Technology, an M.D. from McGill University, and an M.B.A. from the Wharton School of Business at the University of Pennsylvania.
- Alise Reicin
-
Alise Reicin，曾担任Tectonic Therapeutic总裁兼首席执行官，并担任其董事会成员。2018年11月至2019年12月，Reicin博士在Celgene担任总裁，在此之前，在EMD Serono担任高级副总裁、临床开发全球负责人。Reicin博士还曾担任默沙东公司肿瘤特许经营、项目和管道领导、默沙东研究实验室副总裁一职。在她任职期间，她领导了导致Keytruda首次获得批准的初步开发和备案活动在美国和欧盟。Reicin博士也是Sana Biotherapeutics的董事会成员，此前曾是Homology Medicines的董事会成员。Alise Reicin是哥伦比亚医学院的全职教员，也是哥伦比亚长老会医院的医生和研究员。她获得了哈佛医学院的医学博士学位和哥伦比亚大学巴纳德学院的生物化学学士学位。
Alise Reicin joined Immatics' Board of Directors in 2024. Since August 2020, Dr. Reicin has served as President and CEO of Tectonic Therapeutic and as a member of its board of directors. From November 2018 to December 2019, Dr. Reicin served as President at Celgene and prior to that, as Senior Vice President, Global Head of Clinical Development at EMD Serono. Dr. Reicin also held the position of Vice President, Project and Pipeline Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda in the United States and European Union. Dr. Reicin is also a member of the board of directors of Sana Biotherapeutics and previoly was a member of the board of directors of Homology Medicines. Alise Reicin was a full time faculty member at Columbia Medical School as ll as a physician and researcher at Columbia Presbyterian Hospital. She received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University. - Alise Reicin，曾担任Tectonic Therapeutic总裁兼首席执行官，并担任其董事会成员。2018年11月至2019年12月，Reicin博士在Celgene担任总裁，在此之前，在EMD Serono担任高级副总裁、临床开发全球负责人。Reicin博士还曾担任默沙东公司肿瘤特许经营、项目和管道领导、默沙东研究实验室副总裁一职。在她任职期间，她领导了导致Keytruda首次获得批准的初步开发和备案活动在美国和欧盟。Reicin博士也是Sana Biotherapeutics的董事会成员，此前曾是Homology Medicines的董事会成员。Alise Reicin是哥伦比亚医学院的全职教员，也是哥伦比亚长老会医院的医生和研究员。她获得了哈佛医学院的医学博士学位和哥伦比亚大学巴纳德学院的生物化学学士学位。
- Alise Reicin joined Immatics' Board of Directors in 2024. Since August 2020, Dr. Reicin has served as President and CEO of Tectonic Therapeutic and as a member of its board of directors. From November 2018 to December 2019, Dr. Reicin served as President at Celgene and prior to that, as Senior Vice President, Global Head of Clinical Development at EMD Serono. Dr. Reicin also held the position of Vice President, Project and Pipeline Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda in the United States and European Union. Dr. Reicin is also a member of the board of directors of Sana Biotherapeutics and previoly was a member of the board of directors of Homology Medicines. Alise Reicin was a full time faculty member at Columbia Medical School as ll as a physician and researcher at Columbia Presbyterian Hospital. She received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.
- Franois Nader
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Daniel Lochner
Daniel Lochner自2019年7月起担任我们的首席财务官。此前，Lochner先生是高盛（Goldman Sachs）投资管理部门的常务董事，他在该部门担任各种基金策略的首席股票投资组合经理和梦百合投资者。Lochner先生于2005年加入高盛（Goldman Sachs）的投资管理部门，担任股票投资者，他在该公司任职期间一直担任该职位。Lochner先生在里士满大学（University of Richmond）获得经济学学士学位，并在哥伦比亚大学（Columbia University）获得执行工商管理硕士学位。
Daniel Lochner has served as our Chief Financial Officer since July 2019. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.- Daniel Lochner自2019年7月起担任我们的首席财务官。此前，Lochner先生是高盛（Goldman Sachs）投资管理部门的常务董事，他在该部门担任各种基金策略的首席股票投资组合经理和梦百合投资者。Lochner先生于2005年加入高盛（Goldman Sachs）的投资管理部门，担任股票投资者，他在该公司任职期间一直担任该职位。Lochner先生在里士满大学（University of Richmond）获得经济学学士学位，并在哥伦比亚大学（Columbia University）获得执行工商管理硕士学位。
- Daniel Lochner has served as our Chief Financial Officer since July 2019. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.
- Alise Reicin
Alise Reicin，曾担任Tectonic Therapeutic总裁兼首席执行官，并担任其董事会成员。2018年11月至2019年12月，Reicin博士在Celgene担任总裁，在此之前，在EMD Serono担任高级副总裁、临床开发全球负责人。Reicin博士还曾担任默沙东公司肿瘤特许经营、项目和管道领导、默沙东研究实验室副总裁一职。在她任职期间，她领导了导致Keytruda首次获得批准的初步开发和备案活动在美国和欧盟。Reicin博士也是Sana Biotherapeutics的董事会成员，此前曾是Homology Medicines的董事会成员。Alise Reicin是哥伦比亚医学院的全职教员，也是哥伦比亚长老会医院的医生和研究员。她获得了哈佛医学院的医学博士学位和哥伦比亚大学巴纳德学院的生物化学学士学位。
Alise Reicin joined Immatics' Board of Directors in 2024. Since August 2020, Dr. Reicin has served as President and CEO of Tectonic Therapeutic and as a member of its board of directors. From November 2018 to December 2019, Dr. Reicin served as President at Celgene and prior to that, as Senior Vice President, Global Head of Clinical Development at EMD Serono. Dr. Reicin also held the position of Vice President, Project and Pipeine Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda in the United States and European Union. Dr. Reicin is also a member of the board of directors of Sana Biotherapeutics and previoly was a member of the board of directors of Homology Medicines. Alise Reicin was a full time faculty member at Columbia Medical School as ll as a physician and researcher at Columbia Presbyterian Hospital. She received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.- Alise Reicin，曾担任Tectonic Therapeutic总裁兼首席执行官，并担任其董事会成员。2018年11月至2019年12月，Reicin博士在Celgene担任总裁，在此之前，在EMD Serono担任高级副总裁、临床开发全球负责人。Reicin博士还曾担任默沙东公司肿瘤特许经营、项目和管道领导、默沙东研究实验室副总裁一职。在她任职期间，她领导了导致Keytruda首次获得批准的初步开发和备案活动在美国和欧盟。Reicin博士也是Sana Biotherapeutics的董事会成员，此前曾是Homology Medicines的董事会成员。Alise Reicin是哥伦比亚医学院的全职教员，也是哥伦比亚长老会医院的医生和研究员。她获得了哈佛医学院的医学博士学位和哥伦比亚大学巴纳德学院的生物化学学士学位。
- Alise Reicin joined Immatics' Board of Directors in 2024. Since August 2020, Dr. Reicin has served as President and CEO of Tectonic Therapeutic and as a member of its board of directors. From November 2018 to December 2019, Dr. Reicin served as President at Celgene and prior to that, as Senior Vice President, Global Head of Clinical Development at EMD Serono. Dr. Reicin also held the position of Vice President, Project and Pipeine Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda in the United States and European Union. Dr. Reicin is also a member of the board of directors of Sana Biotherapeutics and previoly was a member of the board of directors of Homology Medicines. Alise Reicin was a full time faculty member at Columbia Medical School as ll as a physician and researcher at Columbia Presbyterian Hospital. She received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.
- Peter McNamara
Peter McNamara，2021年6月至2022年6月担任Tectonic Therapeutic，Inc.高级副总裁、研究主管。在加入Tectonic之前，他曾于2005年至2021年4月在私营制药公司诺华研究基金会（NIBR，San Diego）的基因组学研究所担任多个职位，最近于2018年6月至2021年4月担任生物治疗和生物技术执行董事，负责管理广泛治疗领域不同模式的大约50个临床前和早期临床药物发现项目组合。在他的职业生涯中，麦克纳马拉博士在获得10多个IND方面发挥了关键作用，其中两个现已获得批准。在加入诺华之前，麦克纳马拉博士曾在私营生物技术公司Phenomix Corporation担任药理学总监。在加入Phenomix之前，他是宾夕法尼亚大学转化医学和治疗研究所的教员。麦克纳马拉博士在戈尔韦的爱尔兰国立大学获得生物化学博士和学士学位。
Peter McNamara,served as Tectonic Therapeutic, Inc. Senior Vice President, Head of Research from June 2021 to June 2022. Prior to joining Tectonic, he held various positions at the Genomics Institute of the Novartis Research Foundation (NIBR, San Diego), a privately held pharmaceutical company, from 2005 to April 2021, most recently as Executive Director of Biotherapeutics and Biotechnology from June 2018 to April 2021 where he served on the executive committee and strategy council responsible for managing a portfolio of approximately 50 preclinical and early- stage clinical drug discovery programs across different modalities in a broad range of therapeutic areas. Over the course of his career, Dr. McNamara has played a critical role in the obtainment of over 10 INDs, two of which are now approved. Prior to Novartis, Dr. McNamara served as Director of Pharmacology at Phenomix Corporation, a privately-held biotechnology company. Prior to Phenomix, he was a faculty member of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. Dr. McNamara earned both a Ph.D. and B.S. in Biochemistry from the National University of Ireland, at Galway.- Peter McNamara，2021年6月至2022年6月担任Tectonic Therapeutic，Inc.高级副总裁、研究主管。在加入Tectonic之前，他曾于2005年至2021年4月在私营制药公司诺华研究基金会（NIBR，San Diego）的基因组学研究所担任多个职位，最近于2018年6月至2021年4月担任生物治疗和生物技术执行董事，负责管理广泛治疗领域不同模式的大约50个临床前和早期临床药物发现项目组合。在他的职业生涯中，麦克纳马拉博士在获得10多个IND方面发挥了关键作用，其中两个现已获得批准。在加入诺华之前，麦克纳马拉博士曾在私营生物技术公司Phenomix Corporation担任药理学总监。在加入Phenomix之前，他是宾夕法尼亚大学转化医学和治疗研究所的教员。麦克纳马拉博士在戈尔韦的爱尔兰国立大学获得生物化学博士和学士学位。
- Peter McNamara,served as Tectonic Therapeutic, Inc. Senior Vice President, Head of Research from June 2021 to June 2022. Prior to joining Tectonic, he held various positions at the Genomics Institute of the Novartis Research Foundation (NIBR, San Diego), a privately held pharmaceutical company, from 2005 to April 2021, most recently as Executive Director of Biotherapeutics and Biotechnology from June 2018 to April 2021 where he served on the executive committee and strategy council responsible for managing a portfolio of approximately 50 preclinical and early- stage clinical drug discovery programs across different modalities in a broad range of therapeutic areas. Over the course of his career, Dr. McNamara has played a critical role in the obtainment of over 10 INDs, two of which are now approved. Prior to Novartis, Dr. McNamara served as Director of Pharmacology at Phenomix Corporation, a privately-held biotechnology company. Prior to Phenomix, he was a faculty member of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. Dr. McNamara earned both a Ph.D. and B.S. in Biochemistry from the National University of Ireland, at Galway.
- Marcella K. Ruddy
Marcella K. Ruddy，在药物开发的所有临床阶段拥有超过20年的药物开发经验。目前，她自2023年1月起担任Upstream Bio董事会成员，自2025年1月起担任Sionna Therapeutics董事会成员。此前，她曾于2022年8月至2024年8月担任Polarean Imaging的董事会成员。在加入Tectonic之前，Ruddy博士是再生元制药免疫学/炎症治疗领域的临床开发主管。在那个角色中，她领导了Dupixent的临床开发通过超过九个3期试验启动和全球多个监管批准。Ruddy博士在默沙东花了10年时间进行早期开发，并通过临床上的概念验证，从临床前开发中获得了许多化合物。在进入药物开发之前，Ruddy博士是麻省总医院/哈佛医学院肺科的成员，在那里她创立并指导了成人囊性纤维化项目。鲁迪博士在普林斯顿大学获得了A.B.学位，在圣路易斯华盛顿大学获得了医学博士和硕士学位。她在哈佛医学院附属医院完成了内科和肺部研究金培训。
Marcella K. Ruddy,has over 20 years of experience in drug development across all stages of clinical drug development. She currently serves as a member of the board of directors of Upstream Bio since January 2023 and Sionna Therapeutics since January 2025. She previously served on the Board of Directors of Polarean Imaging from August 2022 through August 2024. Prior to joining Tectonic, Dr. Ruddy was the Head of Clinical Development for the Immunology/ Inflammation Therapeutic Area at Regeneron Pharmaceuticals. In that role she led the clinical development of Dupixent through over nine Phase 3 trial initiations and multiple regulatory approvals globally. Dr. Ruddy spent 10 years in early development at Merck and took many compounds from preclinical development through proof of concept in the clinic. Prior to entry into drug development, Dr. Ruddy was a member of the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. Dr. Ruddy earned an A.B. from Princeton University and a M.D. and M.S. from Washington University, St. Louis. She competed her internal medicine and pulmonary fellowship training at Harvard Medical School affiliated hospitals.- Marcella K. Ruddy，在药物开发的所有临床阶段拥有超过20年的药物开发经验。目前，她自2023年1月起担任Upstream Bio董事会成员，自2025年1月起担任Sionna Therapeutics董事会成员。此前，她曾于2022年8月至2024年8月担任Polarean Imaging的董事会成员。在加入Tectonic之前，Ruddy博士是再生元制药免疫学/炎症治疗领域的临床开发主管。在那个角色中，她领导了Dupixent的临床开发通过超过九个3期试验启动和全球多个监管批准。Ruddy博士在默沙东花了10年时间进行早期开发，并通过临床上的概念验证，从临床前开发中获得了许多化合物。在进入药物开发之前，Ruddy博士是麻省总医院/哈佛医学院肺科的成员，在那里她创立并指导了成人囊性纤维化项目。鲁迪博士在普林斯顿大学获得了A.B.学位，在圣路易斯华盛顿大学获得了医学博士和硕士学位。她在哈佛医学院附属医院完成了内科和肺部研究金培训。
- Marcella K. Ruddy,has over 20 years of experience in drug development across all stages of clinical drug development. She currently serves as a member of the board of directors of Upstream Bio since January 2023 and Sionna Therapeutics since January 2025. She previously served on the Board of Directors of Polarean Imaging from August 2022 through August 2024. Prior to joining Tectonic, Dr. Ruddy was the Head of Clinical Development for the Immunology/ Inflammation Therapeutic Area at Regeneron Pharmaceuticals. In that role she led the clinical development of Dupixent through over nine Phase 3 trial initiations and multiple regulatory approvals globally. Dr. Ruddy spent 10 years in early development at Merck and took many compounds from preclinical development through proof of concept in the clinic. Prior to entry into drug development, Dr. Ruddy was a member of the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. Dr. Ruddy earned an A.B. from Princeton University and a M.D. and M.S. from Washington University, St. Louis. She competed her internal medicine and pulmonary fellowship training at Harvard Medical School affiliated hospitals.
- Marc Schwabish
Marc Schwabish，于2018年2月至2020年12月期间担任Fusion Pharmaceuticals Inc.的业务发展和美国运营高级副总裁，其交易包括该公司的B轮融资、首次公开募股，以及与阿斯利康 PLC建立广泛的合作伙伴关系。在任职于Fusion Pharmaceuticals之前，Schwabish博士是拜耳公司的美国制药业务发展主管。他还曾在Eisai Inc.担任业务发展和联盟管理职务，在Leerink Swann担任战略咨询，在RBS担任医疗保健投资银行业务。Schwabish博士获得了康奈尔大学生物科学学士学位。曾获哈佛大学生物化学与分子药理学博士学位。
Marc Schwabish,served as SVP Business Development and US Operations at Fusion Pharmaceuticals Inc. from February 2018 to December 2020 where his transactions, amongst others, included the company's Series B financing, IPO, and an expansive partnership with AstraZeneca plc. Prior to working at Fusion Pharmaceuticals, Dr. Schwabish was Head of U.S. Pharma Business Development at Bayer, Inc. He also held roles in Business Development and Alliance Management at Eisai Inc., Strategy Consulting at Leerink Swann, and Healthcare Investment Banking at RBS. Dr. Schwabish earned a B.S. in Biological Sciences from Cornell University. He earned a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard University.- Marc Schwabish，于2018年2月至2020年12月期间担任Fusion Pharmaceuticals Inc.的业务发展和美国运营高级副总裁，其交易包括该公司的B轮融资、首次公开募股，以及与阿斯利康 PLC建立广泛的合作伙伴关系。在任职于Fusion Pharmaceuticals之前，Schwabish博士是拜耳公司的美国制药业务发展主管。他还曾在Eisai Inc.担任业务发展和联盟管理职务，在Leerink Swann担任战略咨询，在RBS担任医疗保健投资银行业务。Schwabish博士获得了康奈尔大学生物科学学士学位。曾获哈佛大学生物化学与分子药理学博士学位。
- Marc Schwabish,served as SVP Business Development and US Operations at Fusion Pharmaceuticals Inc. from February 2018 to December 2020 where his transactions, amongst others, included the company's Series B financing, IPO, and an expansive partnership with AstraZeneca plc. Prior to working at Fusion Pharmaceuticals, Dr. Schwabish was Head of U.S. Pharma Business Development at Bayer, Inc. He also held roles in Business Development and Alliance Management at Eisai Inc., Strategy Consulting at Leerink Swann, and Healthcare Investment Banking at RBS. Dr. Schwabish earned a B.S. in Biological Sciences from Cornell University. He earned a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard University.